Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Clinical trial NCT03145064 · COMPLETED

Trial details

NCT number: NCT03145064
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma

Start date: 2017-06-30
Primary completion: 2019-05-24
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.